Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study)

Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study)

Background/aims To describe the functional outcomes of patients with diabetic macular oedema (DME) non-responsive to bevacizumab switched to ranibizumab or aflibercept over 1 year and the demographic and anatomic predictors of these functional outcomes.Methods In a retrospective real-world cohort st...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Qiang Soh, Zheng Xian Thng, Wei Kiong Ngo, Colin S Tan, Tock Han Lim, Louis W Lim, Augustinus Laude, Darren Choy, Wen Jun Song, Helen Fang Mi, Koh Lilian, Jacob Yu Hang Chin, Karen Jhi Wen Chia, Issac Too, Nicola Y Gan, Rajesh Rajagopalan
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:BMJ Open Ophthalmology
Online Access:https://bmjophth.bmj.com/content/10/1/e002178.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://bmjophth.bmj.com/content/10/1/e002178.full

Similar Items